Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma

SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide with slow progress in the development of effective therapies. The breakthrough IMbrave150 trial established atezolizumab plus bevacizumab as the standard of care first-line therapy for patients with u...

Descripción completa

Detalles Bibliográficos
Autores principales: Manzar, Gohar Shahwar, De, Brian Sandeep, Abana, Chike Osita, Lee, Sunyoung S., Javle, Milind, Kaseb, Ahmed O., Vauthey, Jean-Nicolas, Tran Cao, Hop Sanderson, Koong, Albert C., Smith, Grace Li, Taniguchi, Cullen M., Holliday, Emma Brey, Das, Prajnan, Koay, Eugene Jon, Ludmir, Ethan Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032898/
https://www.ncbi.nlm.nih.gov/pubmed/35454808
http://dx.doi.org/10.3390/cancers14081901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032898/
https://www.ncbi.nlm.nih.gov/pubmed/35454808
http://dx.doi.org/10.3390/cancers14081901

Ejemplares similares